Company: PTPI
Filing Date: 2025-01-24
Form Type: S-1
Source: 0001410578-25-000047
Chunk: 165

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-01-24
Form: S-1
Chunk 165
---
 | ​ | $    | 2,857,498 | ​ | $                         |    7,663,915 | ​ | $    | 10,613,962 | ​ |

Gross billings has limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of the Company’s results as reported under GAAP.

99

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE The Board Our Board currently consists of three members (each, a “Director”): Joshua N. Silverman, Bruce T. Bernstein and Wayne R. Walker. Under the amended and restated by-laws of the Company (the “By-Laws”), the number of Directors is fixed from time to time by resolution of the Board or the stockholders at an annual meeting of the stockholders, and Directors serve until the next annual election and their successors are duly elected and qualified, or until their earlier resignation, removal or death. Below is a list of the names, ages and positions of the individuals who currently serve as our Directors.

| Name                |   | Age |   | Position              |   |
| Joshua N. Silverman | ​ |  54 | ​ | Chairman of the Board | ​ |
| ​                   | ​ |   ​ | ​ | ​                     | ​ |
| Bruce T. Bernstein  | ​ |  60 | ​ | Director              | ​ |
| ​                   | ​ |   ​ | ​ | ​                     | ​ |
| Wayne R. Walker     | ​ |  65 | ​ | Director              | ​ |

Director Biographies Information concerning our Directors is set forth below. The biographical description of each Director includes the specific experience, qualifications, attributes and skills that led the Board to conclude that such person should serve as a Director. Joshua N. Silverman- Mr. Silverman joined Petros as a Director and Vice Chairman of the Board in December 2020 and currently serves as the Company’s Chairman of the Board. Mr. Silverman currently serves as the managing member of Parkfield Funding LLC. Mr. Silverman has also served as Interim Chairman, Interim Chief Executive Officer and Interim President of PharmaCyte Biotech, Inc. (Nasdaq: PMCB) since October 2022 and as a director since August 2022. Mr. Silverman was the co-founder, and a principal and managing partner of Iroquois Capital Management, LLC (“Iroquois